Cantor Fitzgerald resumed coverage on Pliant Therapeutics
$PLRX
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald resumed coverage of Pliant Therapeutics with a rating of Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2025 | Neutral → Underweight | Analyst | |
| 3/4/2025 | Buy → Hold | Needham | |
| 3/4/2025 | Neutral | Cantor Fitzgerald | |
| 3/3/2025 | Buy → Hold | Stifel | |
| 3/3/2025 | Outperform → Market Perform | Leerink Partners | |
| 2/10/2025 | Overweight → Neutral | Analyst | |
| 2/10/2025 | $43.00 → $4.00 | Buy → Hold | Canaccord Genuity |
| 2/10/2025 | Outperform → Perform | Oppenheimer |
10-Q - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
DEFA14A - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026. Poster Presentation Title: Cohort Expansion of a Phase I Study of PLN-101095, a First-in-Class Dual αvβ8 /αvβ1 Integrin Inhibitor, in Combination with Pembrolizumab in Patients with Advanced Solid Tumors Refractory to Immune Checkpoint Inhibitors Presenter:Timothy A. Yap, MBBS, Ph.D., Univer
RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability to date.Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors.MELBOURNE, Australia, May 15, 2026 /PRNewswire/ -- Atisama Therapeutics (formerly Rage Bio) ("Atisama" or the "Company"), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today reported progress in the Phase 1 study of its lead candidate, RB042, and announced the appointment of Dr. Bernard Coulie as Chair of the Board of Dire
First participant dosed in FORTIFY, a Phase 1b indication expansion trial of PLN-101095Oral presentation at AACR 2026 featured updated data from Phase 1 trial of PLN-101095 showing deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors PLN-101095 spotlighted as novel IO approach as part of AACR's 2026 Highlights Plenary Session SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported first quarter 2026 financial results. "In the first quarter, our team showcas
Analyst downgraded Pliant Therapeutics from Neutral to Underweight
Needham downgraded Pliant Therapeutics from Buy to Hold
Cantor Fitzgerald resumed coverage of Pliant Therapeutics with a rating of Neutral
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerability to date.Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors.MELBOURNE, Australia, May 15, 2026 /PRNewswire/ -- Atisama Therapeutics (formerly Rage Bio) ("Atisama" or the "Company"), an Australian clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today reported progress in the Phase 1 study of its lead candidate, RB042, and announced the appointment of Dr. Bernard Coulie as Chair of the Board of Dire
PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported fourth quarter 2025 financial results. "We ended 2025 with encouraging data from our lead oncology program in ICI-refractory patients, an area of unmet medical need, that informed the initiation of our accelerated
Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2024 financial results. Fourth Quarter and Recent Highlights Bexotegrast Highlights BEACON-IPF discontinued following recommendation from expanded data safety monitoring board (DSMB). Following a prespecified data review and recommendation by the trial's independent DSMB, as well as a secondary r
SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Pliant through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12 The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced
Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the Enhanced Liver Fibrosis (ELF) score and collagen synthesis biomarker PRO-C3 levels relative to placebo at all doses with statistical significance at the 160 mg dose Bexotegrast-treated patients showed improved liver biochemistry and imaging parameters relative to placebo at Week 12 Company to host webcast and conference call today, Tuesday, September 26 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced positive data f